✦ THIS WEEK IN THE THEME · week of Nov 19
Equal-weight day scan -1.56% across quoted names. Open the Daily Brief for cited overnight context; Saturday pipeline can attach a reviewed theme note in Prisma when ready.
Multi-period returns stay — until a grounded history series ships. We do not invent YTD.
Constituents
Delayed public quotes · financials on linked stock pages from SEC XBRL. Empty cells stay —.
| Ticker | Company / role | Last | 1D | Volume |
|---|
| LLY | Eli Lilly and Company Incretin franchise | 1,351.12 | -2.29% | 3.1M |
| NVO | — GLP-1 franchise (ADR) | 38.87 | -1.42% | 16.5M |
| AMGN | — Obesity pipeline exposure | 438.82 | -1.14% | 2.5M |
| PFE | — Metabolic pipeline / partnerships | 27.54 | -1.85% | 35.0M |
| VKTX | — Oral / next-gen candidates | 25.84 | -1.26% | 2.8M |
| GPCR | — Oral GLP-1 candidates | 17.12 | -1.38% | 586K |
- No universe news / 8-K in window
Inclusion rules
- Approved GLP-1 product, disclosed late-stage GLP-1 / incretin program, or first-order manufacturing / delivery exposure named in filings.
- US-listed equity or ADR with Desk quotes.
- Exclude pure clinics or compounding pharmacies without a public equity ticker suitable for the Desk.
- Revisit after major FDA or earnings disclosures that change the product map.
Inclusion is product- and pipeline-driven from public disclosures. The desk does not estimate peak sales. Quote table is equal-weight for scanning only.
FAQ
- Is VKTX / GPCR as liquid as LLY?
- No. Smaller names can gap and print thin volume. The table still shows delayed quotes when available, and shows — when not.
- Do you include compounders?
- Not as basket members. The theme is public equities with filing-traceable exposure.